"CML has become a chronic disease for many pts treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs). However, new approaches are needed to increase the prevalence of deep responses suitable for treatment discontinuation and to treat resistant/recurrent CML. Immune cell–mediated approaches (eg, stem cell transplantation, interferon-α) can be effective. PD-1 ligation provides a negative costimulatory signal governing the balance between T-cell activation and tolerance. The potent second-generation TKI dasatinib may have synergy with nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody. Nivolumab has shown encouraging clinical activity against several solid tumors. PD-1 is upregulated on CD8+ T cells in CML pts (Christiansson PLoS ONE 2013;8:e55818) and blocking the PD-1/ligand interaction prolonged survival in a murine model (Mumprecht Blood 2009;114:1528-36). The study will assess safety, tolerability, and preliminary efficacy of dasatinib + nivolumab in previously treated CML in chronic or accelerated phase (CP/AP). ""
Extrait de An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML)
Voir aussi
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia - ClinicalTrial.gov
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia – National Cancer Institute